|Table of Contents|

Quality evaluation in small hepatocellular carcinoma SBRT

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 23
Page:
4477-4481
Research Field:
Publishing date:

Info

Title:
Quality evaluation in small hepatocellular carcinoma SBRT
Author(s):
WU Jiayu; ZHANG Jianying; CHEN Zhihan; JI Weixing; GAO Yu'nan; LI Tingting; CHEN Yixing
Department of Radiation Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,China.
Keywords:
hepatocellular carcinoma; stereotactic body radiation therapy; plan quality; conformity indices; gradient index
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2024.23.009
Abstract:
Objective:To formulate an achievable recommendations of plan quality indices for different range of target volume which could be applied as a guideline to better radiotherapy plan designing in our clinic.Methods:The SBRT plan of 84 patients with HCC in our center was retrospectively analyzed.The dose estimation indices from guidelines of the American Radiotherapy Collaboration Group(RTOG) and the International Commission on Radiological Units and Measurements(ICRU) including conformity index(CI),homogeneity index(HI),gradient index(GI) and D2 cm were calculated and statistically analyzed.Results:CI fluctuated within a small range of 0.97 to 1.31 which presented no significant correlation with PTV volume globally.GI and D2 cm were significantly correlated with the target volume(P=0.001/P=0.001).As a conclusion,the acceptable ranges of the above evaluation indices for different target volumes are given.Conclusion:The results have small deviation compared with the reference in existing literature and RTOG 0915 guideline.The main benefit of this study is to provide acceptable range of plan quality metrics for liver SBRT apart from prescription dose coverage of PTV and dose limitation of OARs.Therefore,the new guidance formulated for the plan quality indices in liver SBRT paves the way for future clinical trials.

References:

[1]BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
[2]HEIMBAC JK,KULIK LM,FINN RS,et al.AASLD guidelines for the treatment of hepatocellular carcinoma［J］.Hepatology,2018,67(1):358-380.
[3]王维虎,曾昭冲.中国原发性肝细胞癌放射治疗指南(2020年版)［J］.临床肝胆病杂志,2021,37(5):1029-1033. WANG WH,ZENG SC.Chinese radiotherapy guidelines for primary hepatocellular carcinoma(2020 edition)［J］.Journal of Clinical Hepatology,2021,37(5):1029-1033.
[4]中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南(2022年版)［J］.肿瘤综合治疗电子杂志,2022,8(02):16-53. National Health Commission of the People's Republic of China.Standardization for diagnosis and treatment of primary hepatic carcinoma(2022 edition)［J］.Journal of Multidisciplinary Cancer,2022,8(02):16-53.
[5]KATZ AW,WINTER KA,DAWSON LA,et al.RTOG 0438:A phase I trial of highly conformal radiation therapy for patients with liver metastases［J］.Journal of Clinical Oncology,2012,30(4_suppl):257.
[6]ZHOU M,WANG H,ZENG X,et al.Mortality,morbidity,and risk factors in China and its provinces,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017［J］.Lancet(London,England),2019,394(10204):1145-1158.
[7]SEBASTIANN T,XU-WELLIVER M,WILLIAMS TM.Stereotactic body radiation therapy(SBRT) for early stage nonsmall cell lung cancer(NSCLC):contemporary insights and advances［J］.Journal of Thoracic Disease,2018,10(S21):S2451-S2464.
[8]TIMMERMAN RD,KAVANAGH BD,CHO LC,et al.Stereotactic body radiation therapy in multiple organ sites［J］.Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2007,25(8):947-952.
[9]SU TS,LIANG P,LIANG J,et al.Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma［J］.Int J Radiat Oncol Biol Phys,2017,98(3):639-646.
[10]KOOM WS,SEONG J,HAN KH,et al.Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas［J］.Int J Radiat Oncol Biol Phys,2010,77(5):1433-1440.
[11]YAPARPALVI R,GARG MK,SHEN J,et al.Evaluating which plan quality metrics are appropriate for use in lung SBRT［J］.The British Journal of Radiology,2018,91(1083):0170393.
[12]LEASURE JM,ULIZIO V,PEARSON D.Retrospective dosimetric analysis of brain lesions planned in Pinnacle 9.8 via a HDMLC linac［J］.Medical Dosimetry,2019,44(3):e8-e12.
[13]VIDETIC GM,HU C,SINGH A,et al.Radiation therapy oncology group(RTOG) protocol 0915:A randomized phase 2 study comparing 2 stereotactic body radiation therapy(SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer［J］.International Journal of Radiation Oncology Biology Physics,2013,87(2):S3.
[14]BEZJAK A.Seamless phase I/II study of stereotactic lung radiotherapy(SBRT) for early stage,centrally located,non-small cell lung cancer(NSCLC) in medically inoperable patients［J］.RTOG,2012,813:1-75.
[15]CHEN YX,ZHUANG Y,YANG P,et al.Helical IMRT-based stereotactic body radiation therapy using an abdominal compression technique and modified fractionation regimen for small hepatocellular carcinoma［J］.Technology in Cancer Research & Treatment,2020,19(3):153303382093700.
[16]PADDICK I,LIPPITZ B.A simple dose gradient measurement tool to complement the conformity index［J］.Journal of Neurosurgery,2006,105:194-201.
[17]HODAPP N.The ICRU report 83:prescribing,recording and reporting photon-beam intensity-modulated radiation therapy(IMRT)［J］.Strahlentherapie und Onkologie,2012,188(1):97-99.
[18]HURKMANS CW,CUIJPERS JP,LAGERWAARD FJ,et al.Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer:report from the Quality Assurance Working Party of the randomised phase Ⅲ ROSEL study［J］.Radiation Oncology,2009,4(1):1-14.
[19]KYOUNGJUN Y,JUNGWON K,BYUNGCHUL C,et al.Gated volumetric-modulated arc therapy vs tumor-tracking cyberknife radiotherapy as stereotactic body radiotherapy for hepatocellular carcinoma:A dosimetric comparison study focused on the impact of respiratory motion managements［J］.PLoS One,2016,11(11):e0166927.
[20]PAIK EK,KIM MS,CHOI CW,et al.Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma［J］.Radiation Oncology Journal,2015,33(3):233-241.
[21]LEE J,DEAN C,PATEL R,et al.Multi-center evaluation of dose conformity in stereotactic body radiotherapy［J］.Phys Imaging Radiat Oncol,2019,11:41-46.

Memo

Memo:
-
Last Update: 2024-11-01